BXP (BXP) Earnings Dates, Call Summary & Reports

Compare

637 Followers

Earnings Data

Report Date

May 05, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

0.29

Last Year’s EPS

0.39

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 16 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Jan 27, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presents multiple strong operating and strategic positives — robust leasing volumes, a constructive development pipeline with high projected yields, significant progress on a stated $1.9B disposition program, improved liquidity and expected interest cost reductions — which together underpin 2026 FFO guidance that resumes growth. Offsetting items include short-term FFO dilution and NOI reduction from asset sales, elevated leasing/concession costs in some markets (notably parts of the West Coast), a modest Q4 FFO miss driven by higher G&A and tenant reserves, and near-term muted cash same‑property NOI growth. On balance, the company has clear execution on its plan and constructive forward indicators despite near-term noise and regional variability.

Company Guidance

BXP introduced 2026 FFO guidance of $6.88–$7.04 per share (midpoint $6.96, +$0.11 vs. 2025 FFO of $6.85), driven by a projected same‑property NOI gain of 1.25%–2.25% (on $1.88B same‑property NOI, ~+$33M or $0.19 at midpoint), occupancy rising from 86.7% YE‑2025 to ~89% by YE‑2026 (average 87.5%–88.5%), cash same‑property NOI +0%–0.5%, termination income of $11M–$15M, and incremental development NOI of $44M–$52M (midpoint ~$0.27 per share) offset by ~$70M–$74M of NOI loss from asset sales and $13M NOI loss from properties taken out of service (≈$0.07/share). Guidance assumes ~$360M of 2026 dispositions (net proceeds ≈$230M), resulting in FFO dilution of $0.06–$0.08, lower net interest expense (consolidated interest down $25M–$37M; total net interest expense $581M–$593M), expected consolidated interest savings of $38M–$48M vs. 2025, JV interest at share of $60M–$63M (JV interest savings $11M–$14M), G&A of $176M–$183M (up $13M–$20M, including ~$0.07/share noncash stock‑based amortization), fee income $30M–$34M (down $3M–$7M), free rent $130M–$150M, leasing costs roughly $220M–$250M (TIA/LCs averaging ≈$100/sqft going forward), CapEx $100M–$125M, and balance sheet positioning with ~$1.5B cash on hand and a planned refinancing of a $1B bond (current 10‑yr pricing ~5.5%–5.75%).

Strong Leasing Volume and Pipeline

Q4 leasing of ~1.8 million sq ft and full-year 2025 leasing of >5.5 million sq ft (well above targets). Q4 in-service occupancy rose ~70 bps; year-end 2025 in-service occupancy 86.7% with a plan to reach ~89% by year-end 2026 (≈230 bps increase). Started 2026 with ~1.243 million sq ft of executed leases not yet commenced and expect ~4.0 million sq ft of leasing in 2026. Current negotiations ~1.1–1.2 million sq ft and a discussion pipeline ~1.3 million sq ft; conversion on leases in negotiation ~95%.

Development Pipeline and High-Yield Starts

Eight active development projects totaling ~3.5 million sq ft with BXP investment of ~$3.7 billion. Office developments forecasted to generate >8% unleveraged cash yield on delivery (e.g., 2100 M Street: $55M site purchase, 15-year lease for 75% of 320k sq ft; total dev budget ~$380M, forecast yield >8%). 290 Binney (573k sq ft life science) 100% leased to AstraZeneca, BXP share delivering June 2026 with ~ $500M share investment.

Material Asset Disposition Progress

Investor Day target: $1.9B of dispositions by 2028. To date closed 12 assets for net proceeds >$1.0B ($850M in 2025 and ~$180M in January), 21 transactions closed or well underway with estimated net proceeds ≈$1.25B. Dispositions estimated for 2026 aggregate >$400M. Q4 gains on sale were $208M on $890M of sales; net proceeds from sales ~$800M increased liquidity.

Balance Sheet Liquidity and Deleveraging Actions

Company holds ~$1.5B cash & equivalents. Proceeds being used to reduce debt and to redeem a $1.0B bond maturing this year. Management expects net interest expense to decline $38M–$48M in 2026 versus 2025 and consolidated net interest expense guidance of $581M–$593M for 2026.

2026 FFO Guidance Indicates Return to Growth

2026 FFO guidance of $6.88–$7.04 per share (midpoint $6.96), +$0.11 vs. 2025. Midpoint drivers: same-property NOI growth $0.19/sh, development contribution $0.27/sh, lower interest expense $0.24/sh; partially offset by sales dilution (-$0.41/sh) and increased G&A (-$0.09/sh).

Premier Workplace Market Outperformance

Premier workplace direct vacancy in BXP’s five CBD markets at 11.6%, ~560 bps below the broader market; asking rents for premier workplaces >50% premium vs broader market. Over past 3 years, net absorption for premier workplaces +11.4M sq ft vs -8M sq ft for the balance of market (~19.4M sq ft spread).

Notable Development Leasing Wins

Preleased premier workplace development examples: Sidley Austin committed to 75% of a to‑be-built 320k sq ft at 2100 M Street (D.C.) on a 15‑year lease; 343 Madison already committed to nearly 50% of construction costs with a 29% lease to Starr and another ~16% under LOI, derisking the project and targeting a 7.5%–8% stabilized unleveraged cash return on delivery (2029).

Improving Transaction and Capital Markets

Private office transaction volume improved: significant office sales in Q4 totaled $17.3B, +43% QoQ and +21% YoY. CMBS and debt markets showing tightening spreads and greater availability, supporting dispositions and recapitalizations.

BXP (BXP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BXP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 05, 2026	2026 (Q1)	0.29 / -	0.39	―	―	―
Jan 27, 2026	2025 (Q4)	0.56 / 1.56	-1.45	207.59% (+3.01)	―
Oct 28, 2025	2025 (Q3)	0.41 / -0.77	0.53	-245.28% (-1.30)
Jul 29, 2025	2025 (Q2)	0.41 / 0.56	0.51	9.80% (+0.05)	―
Apr 29, 2025	2025 (Q1)	0.41 / 0.39	0.51	-23.53% (-0.12)
Jan 28, 2025	2024 (Q4)	0.49 / -1.45	0.76	-290.79% (-2.21)
Oct 29, 2024	2024 (Q3)	0.53 / 0.53	-0.71	174.65% (+1.24)
Jul 30, 2024	2024 (Q2)	0.47 / 0.51	0.66	-22.73% (-0.15)
Apr 30, 2024	2024 (Q1)	0.53 / 0.51	0.5	2.00% (+0.01)
Jan 30, 2024	2023 (Q4)	0.61 / 0.76	0.78	-2.56% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BXP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 27, 2026	$65.22	$64.15	-1.64%
Oct 28, 2025	$74.09	$70.36	-5.03%
Jul 29, 2025	$69.78	$65.81	-5.68%
Apr 29, 2025	$63.59	$62.24	-2.13%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BXP (BXP) report earnings?

BXP (BXP) is schdueled to report earning on May 05, 2026, After Close (Confirmed).

What is BXP (BXP) earnings time?

BXP (BXP) earnings time is at May 05, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BXP EPS forecast?

BXP EPS forecast for the fiscal quarter 2026 (Q1) is 0.29.